Rare adenocarcinoma of the breast

Rare adenocarcinoma of the breast encompasses a group of uncommon histological subtypes of breast cancer that arise from the glandular epithelial tissue of the breast. Unlike the more common invasive ductal carcinoma (no special type) and invasive lobular carcinoma, these rare subtypes account for a small fraction of all breast cancers and include entities such as secretory carcinoma, acinic cell carcinoma, mucinous cystadenocarcinoma, and other unusual adenocarcinoma variants. Because of their rarity, these tumors are often challenging to diagnose and may require specialized pathological review to distinguish them from more common breast cancer types. Clinically, rare adenocarcinomas of the breast typically present as a palpable breast mass or may be detected on routine mammographic screening as an abnormal density or architectural distortion. Symptoms can include a breast lump, skin changes, nipple discharge, or axillary lymphadenopathy, though presentation varies depending on the specific histological subtype. Some rare subtypes, such as secretory carcinoma, tend to have a more indolent clinical course and favorable prognosis, while others may behave more aggressively. Treatment generally follows the principles established for breast cancer management and may include surgical resection (lumpectomy or mastectomy), sentinel lymph node biopsy or axillary dissection, radiation therapy, chemotherapy, hormonal therapy, and targeted therapies depending on the tumor's receptor status (estrogen receptor, progesterone receptor, and HER2 status). Due to the rarity of these subtypes, evidence-based treatment guidelines specific to each variant are limited, and management decisions are often individualized based on tumor characteristics, stage at diagnosis, and molecular profiling. Multidisciplinary care involving oncologists, surgeons, pathologists, and genetic counselors is recommended.

Common questions about Rare adenocarcinoma of the breast